Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 605
Recruiting: 316
Ph III recruiting: 30
Growth YoY: +37.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (571)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01856023	HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma(PROCLIVITY02)	terminated	Phase 4	29	Clinigen, Inc.INDUSTRY	1	Dec 5, 2023	clinicaltrials
NCT01683188	HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma(PROCLIVITY01)	terminated	Phase 4	53	Clinigen, Inc.INDUSTRY	1	Feb 1, 2021	clinicaltrials